Literature DB >> 31992566

Inhibition of the SRC Kinase HCK Impairs STAT3-Dependent Gastric Tumor Growth in Mice.

Ashleigh R Poh1, Amy R Dwyer2, Moritz F Eissmann1, Ashwini L Chand1, David Baloyan1, Louis Boon3, Michael W Murrey4, Lachlan Whitehead5, Megan O'Brien1, Clifford A Lowell6, Tracy L Putoczki5, Fiona J Pixley4, Robert J J O'Donoghue7, Matthias Ernst8.   

Abstract

Persistent activation of the latent transcription factor STAT3 is observed in gastric tumor epithelial and immune cells and is associated with a poor patient prognosis. Although targeting STAT3-activating upstream kinases offers therapeutically viable targets with limited specificity, direct inhibition of STAT3 remains challenging. Here we provide functional evidence that myeloid-specific hematopoietic cell kinase (HCK) activity can drive STAT3-dependent epithelial tumor growth in mice and is associated with alternative macrophage activation alongside matrix remodeling and tumor cell invasion. Accordingly, genetic reduction of HCK expression in bone marrow-derived cells or systemic pharmacologic inhibition of HCK activity suppresses alternative macrophage polarization and epithelial STAT3 activation, and impairs tumor growth. These data validate HCK as a molecular target for the treatment of human solid tumors harboring excessive STAT3 activity. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31992566      PMCID: PMC8064588          DOI: 10.1158/2326-6066.CIR-19-0623

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  33 in total

Review 1.  Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map.

Authors:  Jennifer Huynh; Ashwini Chand; Daniel Gough; Matthias Ernst
Journal:  Nat Rev Cancer       Date:  2019-02       Impact factor: 60.716

2.  Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling.

Authors:  Brendan J Jenkins; Dianne Grail; Thao Nheu; Meri Najdovska; Bo Wang; Paul Waring; Melissa Inglese; Rachel M McLoughlin; Simon A Jones; Nicholas Topley; Heinz Baumann; Louise M Judd; Andrew S Giraud; Alex Boussioutas; Hong-Jian Zhu; Matthias Ernst
Journal:  Nat Med       Date:  2005-07-24       Impact factor: 53.440

Review 3.  Multiple roles of STAT3 in cardiovascular inflammatory responses.

Authors:  Cheh Peng Lim; Xin-Yuan Fu
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

4.  Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases.

Authors:  M Schaeffer; M Schneiderbauer; S Weidler; R Tavares; M Warmuth; G de Vos; M Hallek
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

5.  Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.

Authors:  Emma Stuart; Michael Buchert; Tracy Putoczki; Stefan Thiem; Ryan Farid; Joachim Elzer; Dennis Huszar; Paul M Waring; Toby J Phesse; Matthias Ernst
Journal:  Mol Cancer Ther       Date:  2014-01-07       Impact factor: 6.261

6.  Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.

Authors:  M Hallek; C Neumann; M Schäffer; S Danhauser-Riedl; N von Bubnoff; G de Vos; B J Druker; K Yasukawa; J D Griffin; B Emmerich
Journal:  Exp Hematol       Date:  1997-12       Impact factor: 3.084

7.  A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo.

Authors:  Yoriko Saito; Hitomi Yuki; Mitsuo Kuratani; Yoshinobu Hashizume; Shinsuke Takagi; Teruki Honma; Akiko Tanaka; Mikako Shirouzu; Junko Mikuni; Noriko Handa; Ikuko Ogahara; Akiko Sone; Yuho Najima; Yuri Tomabechi; Motoaki Wakiyama; Naoyuki Uchida; Mariko Tomizawa-Murasawa; Akiko Kaneko; Satoshi Tanaka; Nahoko Suzuki; Hiroshi Kajita; Yuki Aoki; Osamu Ohara; Leonard D Shultz; Takehiro Fukami; Toshio Goto; Shuichi Taniguchi; Shigeyuki Yokoyama; Fumihiko Ishikawa
Journal:  Sci Transl Med       Date:  2013-04-17       Impact factor: 17.956

8.  STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.

Authors:  Matthias Ernst; Meri Najdovska; Dianne Grail; Therese Lundgren-May; Michael Buchert; Hazel Tye; Vance B Matthews; Jane Armes; Prithi S Bhathal; Norman R Hughes; Eric G Marcusson; James G Karras; Songqing Na; Jonathon D Sedgwick; Paul J Hertzog; Brendan J Jenkins
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

9.  Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity.

Authors:  A P Cardoso; M L Pinto; A T Pinto; M I Oliveira; M T Pinto; R Gonçalves; J B Relvas; C Figueiredo; R Seruca; A Mantovani; M Mareel; M A Barbosa; M J Oliveira
Journal:  Oncogene       Date:  2013-05-06       Impact factor: 9.867

10.  Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.

Authors:  Tracy L Putoczki; Stefan Thiem; Andrea Loving; Rita A Busuttil; Nicholas J Wilson; Paul K Ziegler; Paul M Nguyen; Adele Preaudet; Ryan Farid; Kirsten M Edwards; Yeliz Boglev; Rodney B Luwor; Andrew Jarnicki; David Horst; Alex Boussioutas; Joan K Heath; Oliver M Sieber; Irina Pleines; Benjamin T Kile; Andrew Nash; Florian R Greten; Brent S McKenzie; Matthias Ernst
Journal:  Cancer Cell       Date:  2013-08-12       Impact factor: 31.743

View more
  8 in total

1.  Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy.

Authors:  Ashleigh R Poh; Christopher G Love; David Chisanga; James H Steer; David Baloyan; Michaël Chopin; Stephen Nutt; Jai Rautela; Nicholas D Huntington; Nima Etemadi; Megan O'Brien; Ryan O'Keefe; Lesley G Ellies; Christophe Macri; Justine D Mintern; Lachlan Whitehead; Gangadhara Gangadhara; Louis Boon; Ashwini L Chand; Clifford A Lowell; Wei Shi; Fiona J Pixley; Matthias Ernst
Journal:  Sci Adv       Date:  2022-06-22       Impact factor: 14.957

2.  Prognostic Value and Related Regulatory Networks of MRPL15 in Non-Small-Cell Lung Cancer.

Authors:  Yangyang Zeng; Yingying Shi; Lu Xu; Yulan Zeng; Xiao Cui; Yuan Wang; Ningning Yang; Fuxiang Zhou; Yunfeng Zhou
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

3.  Deeper Insights on Alchornea cordifolia (Schumach. & Thonn.) Müll.Arg Extracts: Chemical Profiles, Biological Abilities, Network Analysis and Molecular Docking.

Authors:  Kouadio Ibrahime Sinan; Gunes Ak; Ouattara Katinan Etienne; József Jekő; Zoltán Cziáky; Katalin Gupcsó; Maria João Rodrigues; Luisa Custodio; Mohamad Fawzi Mahomoodally; Jugreet B Sharmeen; Luigi Brunetti; Sheila Leone; Lucia Recinella; Annalisa Chiavaroli; Giustino Orlando; Luigi Menghini; Massimo Tacchini; Claudio Ferrante; Gokhan Zengin
Journal:  Biomolecules       Date:  2021-02-04

Review 4.  Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.

Authors:  Justin F Creeden; Khaled Alganem; Ali S Imami; Nicholas D Henkel; F Charles Brunicardi; Shi-He Liu; Rammohan Shukla; Tushar Tomar; Faris Naji; Robert E McCullumsmith
Journal:  Int J Mol Sci       Date:  2020-11-21       Impact factor: 5.923

Review 5.  Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer.

Authors:  Chunxiao Li; Xiaofei Xu; Shuhua Wei; Ping Jiang; Lixiang Xue; Junjie Wang
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 12.469

Review 6.  Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition.

Authors:  Roger J Daly; Andrew M Scott; Oliver Klein; Matthias Ernst
Journal:  Mol Cancer       Date:  2022-09-29       Impact factor: 41.444

7.  HCK promotes glioblastoma progression by TGFβ signaling.

Authors:  Yang Jiang; Meiqing Lou; Zhenlin Wang; Chenting Ying; Anke Zhang; Houshi Xu
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

8.  Hematopoietic cell kinase enhances osteosarcoma development via the MEK/ERK pathway.

Authors:  Weibo Liu; Teng Li; Wenhao Hu; Quanbo Ji; Fanqi Hu; Qi Wang; Xiaoqing Yang; Dengbin Qi; Hui Chen; Xuesong Zhang
Journal:  J Cell Mol Med       Date:  2021-08-07       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.